Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

• Published in: Infection and drug resistance Vol. 12; pp. 947 - 955
• Main Authors: von Massow, Georg, Garcia-Cehic, Damir, Gregori, Josep, Rodriguez-Frias, Francisco, Macià, María Dolores, Escarda, Ana, Esteban, Juan Ignacio, Quer, Josep
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.04.2019; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Analysis; Antiviral agents; Case Report; Characterization; Direct-Acting Antivirals; Drug resistance; Genetic analysis; Genetic aspects; Genetic distance; Genomes; Genomics; Genotype & phenotype; Genotype 1; Genotypes; HCV; Hepatitis; Hepatitis C; Hepatitis C virus; Hepatology; Laboratories; Mutation; Next-generation sequencing; NS5A protein; Patients; Phylogenetics; Phylogeny; Subtype; Viruses; Equatorial Guinea; Spain; Majorca; HCV; genotype 1; subtype; direct-acting antivirals
• ISSN: 1178-6973; 1178-6973
• DOI: 10.2147/IDR.S195441

Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.